Loading...
Market
How many Prime Edited Ex Vivo T-Cell Therapies will be in development by Prime Medicine and Bristol Myers Squibb by December 31, 2024?
2
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Official announcements from Prime Medicine or Bristol Myers Squibb, clinical trial registries
Story
Prime Medicine and Bristol Myers Squibb Enter $3.5 Billion T-Cell Therapy Collaboration with $110M Upfront
Sep 30, 2024, 12:38 PM
Prime Medicine has entered into a strategic research collaboration and license agreement with Bristol Myers Squibb to develop and commercialize multiple Prime Edited Ex Vivo T-Cell Therapies. Prime Medicine will receive $110 million upfront, consisting of $55 million in cash and $55 million in equity, with the potential for more than $3.5 billion in milestone payments. The milestone payments include $1.4 billion in development milestones and $2.1 billion in commercialization milestones. The equity investment involves approximately 11 million shares at $4.99 per share. This collaboration aims to leverage Prime Medicine's gene editing expertise and Bristol Myers Squibb's cell therapy capabilities.
View original story
Similar markets
1 therapy • 25%
2 therapies • 25%
3 therapies • 25%
More than 3 therapies • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Q4 2025 or later • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Yes • 50%
No • 50%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
1-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Increases by more than 50% • 25%
Increases by 25% to 50% • 25%
Changes by less than 25% • 25%
Decreases • 25%